Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALK-N001 in Advanced Solid Tumors
NCT07529535Phase 1Suspended
- Sponsor
- Zhejiang Anglikang Pharmaceutical
- Start
- Jun 2025
- Primary completion
- Dec 2026
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of QHL-1618 in solid tumor (6 arms), sponsored by Zhejiang Anglikang Pharmaceutical. Primary endpoints: Dose-Limiting Toxicity at 2 years, Incidence of Adverse Events at 2 years and 2 more. Started Jun 2025; status: suspended.
02
Drugs
QHL-1618
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07529535.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07529535.